참고문헌
- Akbari M, Abachizadeh K, Khayamzadeh M, et al (2008). Iran cancer report. Cancer Research Center. Shahid Beheshti University of Medical Sciences. Tehran, Qom: Darolfekr. 101-6.
- Akbari ME, Rafiee M, Khoei MA, et al (2011). Incidence and survival of cancers in the elderly population in Iran: 2001- 2005. Asian Pac J Cancer Prev, 12, 3035-9.
- Alawadi S, Ghabreau L, Alsaleh M, et al (2011). 53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol, 28, 709-715. https://doi.org/10.1007/s12032-010-9505-4
- Buller RE, Skilling JS, Kaliszewski S, et al (1995). Absence of significant germline p53 mutations in ovarian cancer patients. Gynecologic Oncology, 58, 368-74. https://doi.org/10.1006/gyno.1995.1244
- Buyru N, Tezol A, Dalay N (2005). p53 intronic G13964C variant in colon cancer and its association with HPV. Anticancer Res, 25, 2767-9.
- Dehghan R, Hosseinpour Feizi MA, Pouladi N, et al (2014). Association of TP53 (-16ins-Pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri Patients. Pathol Oncol Res, 20.
- Duntas L, Grab-Duntas BM (2006). Risk and prognostic factors for differentiated thyroid cancer. Hell J Nucl Med, 9, 156-62.
- Khayamzadeh M, Khayamzadeh M, Tadayon M, et al (2011). Survival of thyroid cancer and social determinants in Iran, 2001-2005. Asian Pac J Cancer Prev, 12, 95-98.
- Langerod A, Zhao H, Borgan O, et al (2007). TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res, 9, 30. https://doi.org/10.1186/bcr1675
- Legakis I, Syrigos K (2011). Recent advances in molecular diagnosis of thyroid cancer. J Thyroid res, 384213.
- Lehman TA, Haffty BG, Carbone CJ, et al (2000). Elevated frequency and functional activity of a specific germ-line P53 intron mutation in familial breast cancer. Cancer Research, 60, 1062-9.
- Liu X, Sinn HP, Ulmer HU, et al (2004). Intronic TP53 germline sequence variants modify the risk in german breast/ovarian cancer families. Hered Cancer Clin Pract, 2, 139-45. https://doi.org/10.1186/1897-4287-2-3-139
- Lowenstein D, Kasper D, Braunwald E, et al (2008). Harrison's principles of internal medicine. McGraw-hill Medical Publishing Division, New Delhi.
- Machado-Silva A, Perrier S, Bourdon JC (2010). P53 family members in cancer diagnosis and treatment. Semin Cancer Biol, 20, 57-62. https://doi.org/10.1016/j.semcancer.2010.02.005
- Malkinson AM, You M (1994). The intronic structure of cancer-related genes regulates susceptibility to cancer. Mol Carcinog, 10, 61-5. https://doi.org/10.1002/mc.2940100202
- Marsh A, Spurdle AB, Turner BC, et al (2001). The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Research, 3, 346-9. https://doi.org/10.1186/bcr319
- Montagna C, Di Cristofano A (2011). Thyrocyte-specific inactivation of P53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget, 2, 1109-26. https://doi.org/10.18632/oncotarget.380
- Nikiforov YE, Biddinger PW, Thompson LDR (2009). Diagnostic pathology and molecular genetics of the thyroid. Baltimore, MD: Lippincott Williams and Wilkins, 94-102.
- Olivier M, Goldgar DE, Sodha N, et al (2003). Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res, 63, 6643-50.
- Olivier M, Hainaut P (2001). TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol, 11, 353-60. https://doi.org/10.1006/scbi.2001.0390
- Olivier M, Langerod A, Carrieri P, et al (2006). The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res, 12, 1157-67. https://doi.org/10.1158/1078-0432.CCR-05-1029
- Parameswaran R, Brooks S, Sadler GP (2010). Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg, 8, 186-93. https://doi.org/10.1016/j.ijsu.2010.01.005
- Pouladi N, Kouhsari SM, Feizi MH, Gavgani RR, Azarfam P (2013). Overlapping region of p53/wrap53 transcripts: mutational analysis and sequence similarity with microRNA-4732-5p. Asian Pac J Cancer Prev, 14, 3503-7. https://doi.org/10.7314/APJCP.2013.14.6.3503
- Pouladi N, Kouhsari SM, Feizi MH, et al (2014). Lack of association of intron 3 16 bp polymorphism of TP53 with breast cancer among Iranian-Azeri patients. Asian Pac J Cancer Prev, 15, 2631-4. https://doi.org/10.7314/APJCP.2014.15.6.2631
- Radha RK, P V, B K (2014). Histopathology and prognostic indices of carcinoma breast with special reference to p53 marker. J Clin Diagn Res, 7, 4-8.
- Sedaie Bonab A, Pouladi N, Hosseinpourfeizi MA, et al (2014). Single-strand conformational polymorphism analysis of a common single nucleotide variation in WRAP53 gene, rs2287499, and evaluating its association in relation to breast cancer risk and prognosis among Iranian-Azeri population. Med Oncol, 31, 168 https://doi.org/10.1007/s12032-014-0168-4
- Shin MK, Kim JW (2014). Clinicopathologic and diagnostic significance of p53 protein expression in papillary thyroid carcinoma. Asian Pac J Cancer Prev, 15, 2341-4. https://doi.org/10.7314/APJCP.2014.15.5.2341
- Sipos JA, Mazzaferri EL (2010). Thyroid cancer epidemiology and prognostic variables. Clinical Oncology, 22, 395-404. https://doi.org/10.1016/j.clon.2010.05.004
- Stegh AH (2012). Targeting the P53 signaling pathway in cancer therapy - The promises, challenges, and perils. Expert Opin Ther Targets, 16, 67-83. https://doi.org/10.1517/14728222.2011.643299
- Surekha D, Sailaja K, Rao DN, et al (2011). Codon 72 and G13964C intron 6 polymorphisms of TP53 in relation to development and progression of breast cancer in India. Asian Pac J Cancer Prev, 12, 1893-8.
- Trifa F, Karray-Chouayekh S, Mabrouk I, et al (2010). Haplotype analysis of P53 polymorphisms: Arg72Pro, Ins16bp and G13964C inTunisian patients with familial or sporadic breast cancer. Cancer Epidemiol, 34, 184-88. https://doi.org/10.1016/j.canep.2010.02.007
- Varley JM, McGown G, Thorncroft M, et al (2001). Significance of intron 6 sequence variations in the TP53 gene in Li-Fraumeni syndrome. Cancer Genet Cytogenet, 129, 85-7. https://doi.org/10.1016/S0165-4608(01)00428-9
- Walsh T, Casadei S, Coats KH, et al (2006). Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. J Am Med Association, https://doi.org/10.1001/jama.295.12.1379